Lavomax [Tilorone]


Lavomax is an immunomodulating and antiviral drug intended for treatment and prevention of respiratory and other viral diseases.Its active ingredient (tilorone) , stimulates the production of interferons (proteins essential for anti-viral defence) and enhances the immunity during influenza and ARVI. 

Research demonstrated that Lavomax is effective in treating viral infections, including influenza and other acute respiratory viral infections, hepatitis and herpes, cytomegalovirus and neurotropic viruses. The drug inhibits viral translation in the infected cells and prevents the spread of viruses, thus showing a strong antiviral effect.


As part of complex therapy of:


  • influenza and ARVI;
  • herpes.
  • Prevention of influenza and ARVI.
  • The drug can also be used as part of complex therapy of viral hepatitis A, B and C, cytomegalovirus infection and non-gonococcal urethritis.


    Active ingredient: tilorone dihydrochloride 125 mg.

    Pharmacodynamic properties

    Lavomax stimulates the production of alpha, beta, and gamma types of interferons in intestinal epithelial cells, hepatocytes, T-cells and neutrophils.

    It also contributes to the growth of bone marrow cells and enhances antibody production, stabilizes the level of immunosuppression and regulates the T-Lymphocyte Helper/Suppressor ratio.


    1 tablet per day during the first 2 days, then 1 tablet once every 2 days.

    To be administered orally after meal.

    Maximum dose for influenza and ARVI treatment course is 750 mg (6 tablets).

    Maximum dose for herpes and other viral infections treatment course is 1.25–2.5 mg (10–20 tablets).

    Side effects

    • Allergic response;
    • dyspepsia:
    • short-term chills.


    • Hypersensitivity to tilorone and other components of the drug.
    • Pregnancy and lactation.
    • Children under 18 years of age.
    • Sucrase-isomaltase deficiency, fructose intolerance or glucose-galactose malabsorption (the drug contains sucrose).